Trump Signs Executive Order to Accelerate FDA Review of Psychedelic Therapies
President Donald Trump signed an executive order Saturday directing the FDA to speed up its review of certain psychedelic compounds. The order, titled “Accelerating Medical Treatments for Serious Mental Illness,” targets drugs already holding breakthrough therapy designation. Trump framed the move as a response to the mental health crisis facing American veterans, while skeptical advocates across the psychedelic therapy space watch the action closely. The order signals a notable shift in federal posture toward psychedelic medicine.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | Details |
|---|---|
| What happened | Trump signed an executive order directing the FDA to issue National Priority Vouchers to psychedelics with breakthrough therapy designation |
| Voucher effect | National Priority Vouchers can compress FDA review from roughly 6 to 10 months down to 1 to 2 months |
| Right to Try | The order opens a Right to Try pathway for eligible patients to access psychedelic drugs, including ibogaine |
| Federal funding | HHS will allocate at least $50 million through ARPA-H to partner with states advancing psychedelic research |
| Rescheduling | The Attorney General must fast track rescheduling review for any Schedule I psychedelic that completes Phase 3 |
| Ibogaine status | Ibogaine remains Schedule I but gains a clear federal pathway for regulated access and research |
New: Get Pre-Screened for a Psychedelic Clinical Trial
What the Order Actually Does
The executive order tells the FDA to issue National Priority Vouchers to psychedelics carrying breakthrough therapy status. These vouchers can shrink the agency’s review window from months to weeks. Trump said the reforms would dramatically expand access to new research. He pointed to veterans and those with severe depression as primary beneficiaries. He also cited the veteran suicide rate in his remarks. The order also directs HHS, FDA and the Department of Veterans Affairs to share clinical trial data. That collaboration is designed to speed real world evidence generation.
Which Psychedelics Are Affected
The FDA has granted breakthrough therapy designation to multiple psychedelic candidates still in clinical trials. Every compound on that list qualifies for priority review under the new order. The current roster includes:
- MDMA for post traumatic stress disorder, first designated in 2017
- Psilocybin (COMP360) from Compass Pathways for treatment resistant depression
- Psilocybin from the Usona Institute for major depressive disorder
- CYB003 from Helus Pharma, a psilocybin analog for major depressive disorder
- Luvesilocin (RE104) from Reunion Neuroscience for postpartum depression
- BPL-003 from AtaiBeckley, an intranasal mebufotenin spray for treatment resistant depression
- DT120 from Definium Therapeutics, an LSD based compound for generalized anxiety disorder
Most of these candidates sit in Phase 2 or Phase 3 trials. Spravato, the esketamine nasal spray from Johnson & Johnson, previously held breakthrough status but received full FDA approval in 2019.
A Specific Push on Ibogaine
The order singles out ibogaine compounds throughout the text. Ibogaine is a naturally occurring compound derived from an African shrub. Practitioners abroad use it to treat addiction, depression, PTSD and traumatic brain injury. The drug remains Schedule I in the United States, grouped alongside heroin. That classification is not changing under the current plan. The FDA and DEA must establish a Right to Try pathway for eligible patients. Treating physicians and researchers can receive Schedule I handling authorizations. Texas has led state level action, with Governor Greg Abbott approving $50 million for ibogaine research last year.
Why the Ketamine Industry Should Pay Attention
Ketamine remains the only legal psychedelic medicine widely available in the United States. It sits years ahead of MDMA, psilocybin and ibogaine in terms of clinical access. The regulatory tone around this order still matters for clinic operators. A friendlier FDA posture toward breakthrough therapies signals broader federal openness. Faster review timelines and new funding benefit the entire field. Clinics offering ketamine assisted therapy may soon operate alongside new approved options.
Safety Concerns Still Loom
Ibogaine carries serious cardiac risks that cannot be ignored. Reviews have documented dangerous heart rhythm disturbances and at least 27 reported deaths. One Stanford study of 30 veterans paired the drug with intravenous magnesium and reported no serious cardiac events. Researchers need larger trials before clinicians can confirm safety protocols. Federal funding through ARPA-H could finally provide the data the field has lacked.
